PharMerica to Present at the 32nd Annual J.P. Morgan Healthcare Conference

PharMerica to Present at the 32nd Annual J.P. Morgan Healthcare Conference

PharMerica CorporationDavid W. Froesel, Jr., 502-627-7950Executive Vice President,Chief Financial Officer and Treasurer

PharMerica Corporation (NYSE:PMC), a national provider of institutional, specialty home infusion, and oncology pharmacy services, today announced that Gregory Weishar, Chief Executive Officer, will make a presentation regarding the Company at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 16, 2014, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time).

The Company also announced that a live broadcast of its conference presentation, as well as any written materials accompanying the presentation, will be available on the “For Investors” tab of the Company’s website, , under “Webcasts and Presentations.” In addition, the webcast, transcript and written materials will be archived on the Company’s website following the event.

PharMerica Corporation is a leading institutional pharmacy services company that services healthcare facilities in the United States, provides pharmacy management services to hospitals and specialty infusion services to patients outside a hospital setting, and offers the only national oncology pharmacy in the U.S. PharMerica operates 95 institutional pharmacies and 12 specialty infusion centers in 45 states. PharMerica’s customers are institutional healthcare providers, such as skilled nursing facilities, nursing centers, assisted living facilities, hospitals, individuals receiving in-home care and other long-term alternative care providers.

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.